Zometa for multiple myeloma – pro
Zometa is FDA indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy.. It is also supported in the literature, that says that the treatment of patients with newly diagnosed multiple myeloma with Zometa® (zoledronic acid) may improve overall survival and progression-free survival. … Zometa is a bisphosphonate drug that is commonly used to reduce the risk of bone complications from bone metastases or multiple myeloma.
Morgan GJ, Davies FE, Gregory WM, et al. First-line treatment with zoledronic acid as compared with clodronate in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. The Lancet [early online publication]. December 4, 2010.